{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:04:15Z","timestamp":1791083055120,"version":"4.1.0"},"reference-count":95,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.4103\/1673-5374.375299","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T08:10:01Z","timestamp":1685002201000},"page":"16-21","source":"Crossref","is-referenced-by-count":56,"title":["Type-B monoamine oxidase inhibitors in neurological diseases"],"prefix":"10.4103","volume":"19","author":[{"given":"Marika","family":"Alborghetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfranco","family":"De Carolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco E.","family":"Pontieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domiziana","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20230626","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/JPD-202224","article-title":"A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice:The SYNAPSES trial","volume":"11","author":"Abbruzzese","year":"(2021)","journal-title":"J Parkinsons Dis"},{"key":"R2-3-20230626","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s12031-020-01544-5","article-title":"Selegiline (L-deprenyl) mitigated oxidative stress, cognitive abnormalities, and histopathological change in rats:alternative therapy in transient global ischemia","volume":"70","author":"Ahmari","year":"(2020)","journal-title":"J Mol Neurosci"},{"key":"R3-3-20230626","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different generations of type-B monoamine oxidase inhibitors in Parkinson's disease:from bench to bedside","volume":"17","author":"Alborghetti","year":"(2019)","journal-title":"Curr Neuropharmacol"},{"key":"R4-3-20230626","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease:a review","volume":"323","author":"Armstrong","year":"(2020)","journal-title":"JAMA"},{"key":"R5-3-20230626","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/j.ncl.2008.05.002","article-title":"Elucidating the mechanism of action and potential interactions of MAO-B inhibitors","volume":"26","author":"Bainbridge","year":"(2008)","journal-title":"Neurol Clin"},{"key":"R6-3-20230626","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3233\/JPD-202004","article-title":"GDNF and Parkinson's disease:where next?A summary from a recent workshop","volume":"10","author":"Barker","year":"(2020)","journal-title":"J Parkinsons Dis"},{"key":"R7-3-20230626","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.3390\/molecules26123724","article-title":"Role of monoamine oxidase activity in Alzheimer's disease:an insight into the therapeutic potential of inhibitors","volume":"26","author":"Behl","year":"(2021)","journal-title":"Molecules"},{"key":"R8-3-20230626","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","article-title":"Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson's disease","volume":"40","author":"Bianchi","year":"(2019)","journal-title":"Neurol Sci"},{"key":"R9-3-20230626","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40263-017-0408-1","article-title":"Safinamide:a review in Parkinson's disease","volume":"31","author":"Blair","year":"(2017)","journal-title":"CNS Drugs"},{"key":"R10-3-20230626","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain","year":"(2014a)","journal-title":"Mov Disord"},{"key":"R11-3-20230626","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease","volume":"29","author":"Borgohain","year":"(2014b)","journal-title":"Mov Disord"},{"key":"R12-3-20230626","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1515\/revneuro-2018-0064","article-title":"Alpha-synuclein in salivary gland as biomarker for Parkinson's disease","volume":"30","author":"Campo","year":"(2019)","journal-title":"Rev Neurosci"},{"key":"R13-3-20230626","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cphy.c140062","article-title":"Channelopathies of skeletal muscle excitability","volume":"5","author":"Cannon","year":"(2015)","journal-title":"Compr Physiol"},{"key":"R14-3-20230626","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/13543776.2018.1427735","article-title":"MAO inhibitors and their wider applications:a patent review","volume":"28","author":"Carradori","year":"(2018)","journal-title":"Expert Opin Ther Pat"},{"key":"R15-3-20230626","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-150700","article-title":"Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson's disease fluctuating patients:post hoc analyses of studies 016 and SETTLE","volume":"6","author":"Cattaneo","year":"(2016)","journal-title":"J Parkinsons Dis"},{"key":"R16-3-20230626","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00415-017-8523-y","article-title":"Efficacy of rasagiline and selegiline in Parkinson's disease:a head-to-head 3-year retrospective case-control study","volume":"264","author":"Cereda","year":"(2017)","journal-title":"J Neurol"},{"key":"R17-3-20230626","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-386467-3.00008-X","article-title":"Rasagiline in Parkinson's disease","volume":"100","author":"Chahine","year":"(2011)","journal-title":"Int Rev Neurobiol"},{"key":"R18-3-20230626","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1093\/brain\/awr177","article-title":"The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration","volume":"134","author":"Cummings","year":"(2011)","journal-title":"Brain"},{"key":"R19-3-20230626","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/phar.1611","article-title":"Clinical outcomes in patients with Parkinson's disease treated with a monoamine oxidase type-B inhibitor:a cross-sectional, cohort study","volume":"35","author":"Dashtipour","year":"(2015)","journal-title":"Pharmacotherapy"},{"key":"R20-3-20230626","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10072-021-05324-w","article-title":"Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients:a prospective longitudinal study","volume":"43","author":"De Micco","year":"(2022)","journal-title":"Neurol Sci"},{"key":"R21-3-20230626","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","article-title":"Biomarkers in Parkinson's disease:Advances and strategies","volume":"22","author":"Delenclos","year":"(2016)","journal-title":"Parkinsonism Relat Disord"},{"key":"R22-3-20230626","doi-asserted-by":"crossref","first-page":"113287","DOI":"10.1016\/j.expneurol.2020.113287","article-title":"Safinamide's potential in treating nondystrophic myotonias:Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo","volume":"328","author":"Desaphy","year":"(2020)","journal-title":"Exp Neurol"},{"key":"R23-3-20230626","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"(2009)","journal-title":"Acta Pharmacol Sin"},{"key":"R24-3-20230626","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrg3460","article-title":"Therapy for Duchenne muscular dystrophy:renewed optimism from genetic approaches","volume":"14","author":"Fairclough","year":"(2013)","journal-title":"Nat Rev Genet"},{"key":"R25-3-20230626","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review:Update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"(2018)","journal-title":"Mov Disord"},{"key":"R26-3-20230626","first-page":"196028","article-title":"Metabotropic glutamate receptors for Parkinson's disease therapy","volume":"2013","author":"Gasparini","year":"(2013)","journal-title":"Parkinsons Dis"},{"key":"R27-3-20230626","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/brainsci11010057","article-title":"SURINPARK:Safinamide for urinary symptoms in Parkinson's disease","volume":"11","author":"G\u00f3mez-L\u00f3pez","year":"(2021)","journal-title":"Brain Sci"},{"key":"R28-3-20230626","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","article-title":"Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy:the PD MED randomized clinical trial","volume":"79","author":"Gray","year":"(2022)","journal-title":"JAMA Neurol"},{"key":"R29-3-20230626","doi-asserted-by":"crossref","first-page":"e2336","DOI":"10.1002\/brb3.2336","article-title":"Effects of safinamide on pain in patients with fluctuating Parkinson's disease","volume":"11","author":"Grigoriou","year":"(2021)","journal-title":"Brain Behav"},{"key":"R31-3-20230626","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/msj.20246","article-title":"Axonal damage in multiple sclerosis","volume":"78","author":"Haines","year":"(2011)","journal-title":"Mt Sinai J Med"},{"key":"R32-3-20230626","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/mds.22402","article-title":"Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease","volume":"24","author":"Hauser","year":"(2009)","journal-title":"Mov Disord"},{"key":"R33-3-20230626","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/00207454.2016.1154552","article-title":"Efficacy of rasagiline in early Parkinson's disease:a meta-analysis of data from the TEMPO and ADAGIO studies","volume":"126","author":"Hauser","year":"(2016)","journal-title":"Int J Neurosci"},{"key":"R34-3-20230626","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1474-4422(12)70039-X","article-title":"Promoting brain remodelling and plasticity for stroke recovery:therapeutic promise and potential pitfalls of clinical translation","volume":"11","author":"Hermann","year":"(2012)","journal-title":"Lancet Neurol"},{"key":"R35-3-20230626","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/17460441.2019.1573984","article-title":"Animal models of ischemic stroke and their impact on drug discovery","volume":"14","author":"Hermann","year":"(2019)","journal-title":"Expert Opin Drug Discov"},{"key":"R36-3-20230626","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1096\/fj.201500079R","article-title":"Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita:a paradigm to understand and treat ion channelopathies","volume":"30","author":"Imbrici","year":"(2016)","journal-title":"FASEB J"},{"key":"R37-3-20230626","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-017-1740-9","article-title":"Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells:different signal pathways for neuroprotection by selegiline and rasagiline","volume":"124","author":"Inaba-Hasegawa","year":"(2017)","journal-title":"J Neural Transm (Vienna"},{"key":"R38-3-20230626","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbr.2018.10.032","article-title":"Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity","volume":"359","author":"Ishikawa","year":"(2019)","journal-title":"Behav Brain Res"},{"key":"R39-3-20230626","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","article-title":"GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease","volume":"20","author":"Jo","year":"(2014)","journal-title":"Nat Med"},{"key":"R40-3-20230626","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","article-title":"Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease","volume":"110","author":"Kennedy","year":"(2003)","journal-title":"J Neural Transm"},{"key":"R41-3-20230626","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0404.1989.tb01787.x","article-title":"The pharmacology of selegiline ((-)deprenyl). New aspects","volume":"126","author":"Knoll","year":"(1989)","journal-title":"Acta Neurol Scand Suppl"},{"key":"R42-3-20230626","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1152\/physrev.00013.2006","article-title":"Mitochondrial membrane permeabilization in cell death","volume":"87","author":"Kroemer","year":"(2007)","journal-title":"Physiol Rev"},{"key":"R43-3-20230626","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/mds.26082","article-title":"Levodopa therapy for Parkinson's disease:Pharmacokinetics and pharmacodynamics","volume":"30","author":"LeWitt","year":"(2015)","journal-title":"Mov Disord"},{"key":"R44-3-20230626","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-386467-3.00004-2","article-title":"The pharmacology of selegiline","volume":"100","author":"Magyar","year":"(2011)","journal-title":"Int Rev Neurobiol"},{"key":"R45-3-20230626","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/B:CEMN.0000012727.59502.c5","article-title":"l-Deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats","volume":"24","author":"Maia","year":"(2004)","journal-title":"Cell Mol Neurobiol"},{"key":"R46-3-20230626","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1093\/hmg\/ddq339","article-title":"Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy","volume":"19","author":"Menazza","year":"(2010)","journal-title":"Hum Mol Genet"},{"key":"R47-3-20230626","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson's disease:an update","volume":"1","author":"Meredith","year":"(2011)","journal-title":"J Parkinsons Dis"},{"key":"R48-3-20230626","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/jpet.117.245100","article-title":"Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia","volume":"364","author":"Morari","year":"(2018)","journal-title":"J Pharmacol Exp Ther"},{"key":"R49-3-20230626","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/awt041","article-title":"Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis","volume":"136","author":"Morsali","year":"(2013)","journal-title":"Brain"},{"key":"R50-3-20230626","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.pnpbp.2009.07.004","article-title":"Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer's disease","volume":"33","author":"Muck-Seler","year":"(2009)","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R51-3-20230626","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00702-020-02150-w","article-title":"Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate \u03b1-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease","volume":"127","author":"Naoi","year":"(2020)","journal-title":"J Neural Transm (Vienna"},{"key":"R52-3-20230626","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.3390\/ijms231911059","article-title":"Neuroprotective function of rasagiline and selegiline, inhibitors of type B monoamine oxidase, and role of monoamine oxidases in synucleinopathies","volume":"23","author":"Naoi","year":"(2022)","journal-title":"Int J Mol Sci"},{"key":"R53-3-20230626","first-page":"23","article-title":"Rasagiline in treatment of Parkinson's disease","volume":"4","author":"Nayak","year":"(2008)","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R54-3-20230626","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1353-8020(01)00024-4","article-title":"Motor fluctuations and dyskinesia in Parkinson's disease","volume":"8","author":"Nutt","year":"(2001)","journal-title":"Parkinsonism Relat Disord"},{"key":"R55-3-20230626","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainres.2017.10.022","article-title":"Role of dopamine on functional recovery in the contralateral hemisphere after focal stroke in the somatosensory cortex","volume":"1678","author":"Obi","year":"(2018)","journal-title":"Brain Res"},{"key":"R56-3-20230626","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"(2009)","journal-title":"N Engl J Med"},{"key":"R57-3-20230626","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuint.2005.11.001","article-title":"Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro","volume":"48","author":"Ono","year":"(2006)","journal-title":"Neurochem Int"},{"key":"R58-3-20230626","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuropharm.2005.04.002","article-title":"MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats","volume":"49","author":"Ossowska","year":"(2005)","journal-title":"Neuropharmacology"},{"key":"R59-3-20230626","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson disease:the TEMPO Study.","volume":"59","year":"2002","journal-title":"Arch Neurol"},{"key":"R60-3-20230626","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","article-title":"A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease","volume":"61","author":"Parkinson","year":"(2004)","journal-title":"Arch Neurol"},{"key":"R61-3-20230626","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons","volume":"57","author":"Rajmohan","year":"(2017)","journal-title":"J Alzheimers Dis"},{"key":"R62-3-20230626","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study):a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"(2005)","journal-title":"Lancet"},{"key":"R63-3-20230626","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"(2014)","journal-title":"Parkinsonism Relat Disord"},{"key":"R64-3-20230626","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"(2021)","journal-title":"Lancet Neurol"},{"key":"R65-3-20230626","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17425255.2017.1273901","article-title":"Use of monoamine oxidase inhibitors in chronic neurodegeneration","volume":"13","author":"Riederer","year":"(2017)","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R66-3-20230626","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10072-017-3123-2","article-title":"Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease:a pilot study","volume":"39","author":"Rinaldi","year":"(2018)","journal-title":"Neurol Sci"},{"key":"R67-3-20230626","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s40520-020-01648-3","article-title":"The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients:a retrospective study","volume":"33","author":"Rinaldi","year":"(2021a)","journal-title":"Aging Clin Exp Res"},{"key":"R68-3-20230626","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-020-02259-y","article-title":"Safinamide improves executive functions in fluctuating Parkinson's disease patients:an exploratory study","volume":"128","author":"Rinaldi","year":"(2021b)","journal-title":"J Neural Transm (Vienna"},{"key":"R70-3-20230626","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/nan.12263","article-title":"Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson's disease","volume":"42","author":"Sadeghian","year":"(2016)","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R71-3-20230626","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/brain\/awaa156","article-title":"Post-stroke deficit prediction from lesion and indirect structural and functional disconnection","volume":"143","author":"Salvalaggio","year":"(2020)","journal-title":"Brain"},{"key":"R72-3-20230626","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"(2008)","journal-title":"Neurobiol Aging"},{"key":"R73-3-20230626","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1007\/s10072-021-05607-2","article-title":"Safinamide improves sleep and daytime sleepiness in Parkinson's disease:results from the SAFINONMOTOR study","volume":"43","author":"Santos","year":"(2022)","journal-title":"Neurol Sci"},{"key":"R74-3-20230626","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations:a randomized clinical trial","volume":"74","author":"Schapira","year":"(2017)","journal-title":"JAMA Neurol"},{"key":"R75-3-20230626","doi-asserted-by":"crossref","first-page":"108024","DOI":"10.1016\/j.neuropharm.2020.108024","article-title":"Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease","volume":"170","author":"Sciaccaluga","year":"(2020)","journal-title":"Neuropharmacology"},{"key":"R76-3-20230626","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0404.1989.tb01798.x","article-title":"Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group","volume":"126","author":"Shoulson","year":"(1989)","journal-title":"Acta Neurol Scand Suppl"},{"key":"R77-3-20230626","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.neuron.2014.08.052","article-title":"Stroke and the connectome:how connectivity guides therapeutic intervention","volume":"83","author":"Silasi","year":"(2014)","journal-title":"Neuron"},{"key":"R78-3-20230626","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.freeradbiomed.2014.07.006","article-title":"Monoamine oxidase inhibition prevents mitochondrial dysfunction and apoptosis in myoblasts from patients with collagen VI myopathies","volume":"75","author":"Sorato","year":"(2014)","journal-title":"Free Radic Biol Med"},{"key":"R79-3-20230626","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1002\/ana.10488","article-title":"Neuroprotection in Parkinson's disease:clinical trials","volume":"53","author":"Stocchi","year":"(2003)","journal-title":"Ann Neurol"},{"key":"R80-3-20230626","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/ene.12205","article-title":"Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease","volume":"21","author":"Stocchi","year":"(2014)","journal-title":"Eur J Neurol"},{"key":"R81-3-20230626","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","article-title":"Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease","volume":"125","author":"Sz\u00f6k\u0151","year":"(2018)","journal-title":"J Neural Transm (Vienna"},{"key":"R82-3-20230626","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00702-019-02082-0","article-title":"Selegiline:a molecule with innovative potential","volume":"127","author":"T\u00e1bi","year":"(2020)","journal-title":"J Neural Transm (Vienna"},{"key":"R83-3-20230626","doi-asserted-by":"crossref","first-page":"10226","DOI":"10.3390\/ijms221910226","article-title":"Plasticity-enhancing effects of levodopa treatment after stroke","volume":"22","author":"Talhada","year":"(2021)","journal-title":"Int J Mol Sci"},{"key":"R84-3-20230626","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease:past, present, and future","volume":"12","author":"Tan","year":"(2022)","journal-title":"J Parkinsons Dis"},{"key":"R85-3-20230626","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.1576","article-title":"Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants:strategies for the management of treatment-resistant depression","volume":"35","author":"Thomas","year":"(2015)","journal-title":"Pharmacotherapy"},{"key":"R86-3-20230626","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged scaffolds as MAO inhibitors:Retrospect and prospects","volume":"145","author":"Tripathi","year":"(2018)","journal-title":"Eur J Med Chem"},{"key":"R87-3-20230626","doi-asserted-by":"crossref","first-page":"a009365","DOI":"10.1101\/cshperspect.a009365","article-title":"Programmed cell death in Parkinson's disease","volume":"2","author":"Venderova","year":"(2012)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R88-3-20230626","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3389\/fphys.2018.01087","article-title":"Drug repurposing for duchenne muscular dystrophy:the monoamine oxidase B Inhibitor safinamide ameliorates the pathological phenotype in mdx mice and in myogenic cultures from DMD patients","volume":"9","author":"Vitiello","year":"(2018)","journal-title":"Front Physiol"},{"key":"R89-3-20230626","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/mds.27423","article-title":"Detection of \u03b1-synuclein in saliva:the importance of preanalytical assessment","volume":"33","author":"Vivacqua","year":"(2018)","journal-title":"Mov Disord"},{"key":"R90-3-20230626","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0304-3940(93)90496-8","article-title":"Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum","volume":"152","author":"Vizuete","year":"(1993)","journal-title":"Neurosci Lett"},{"key":"R91-3-20230626","doi-asserted-by":"crossref","first-page":"585584","DOI":"10.3389\/fnins.2020.585584","article-title":"Molecular mechanisms of glutamate toxicity in Parkinson's disease","volume":"14","author":"Wang","year":"(2020)","journal-title":"Front Neurosci"},{"key":"R92-3-20230626","doi-asserted-by":"crossref","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease","volume":"4","author":"Wang","year":"(2012)","journal-title":"Sci Transl Med"},{"key":"R93-3-20230626","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/gps.4109","article-title":"Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies","volume":"30","author":"Wesnes","year":"(2015)","journal-title":"Int J Geriatr Psychiatry"},{"key":"R94-3-20230626","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2174\/092986712799462630","article-title":"The role of glutamate signaling in pain processes and its regulation by GCP II inhibition","volume":"19","author":"Wozniak","year":"(2012)","journal-title":"Curr Med Chem"},{"key":"R95-3-20230626","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1749-6632.2000.tb06191.x","article-title":"Effect of MAO-B inhibitors on MPP+toxicity in vivo","volume":"899","author":"Wu","year":"(2000)","journal-title":"Ann N Y Acad Sci"},{"key":"R96-3-20230626","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12640-020-00246-5","article-title":"The protective effect of safinamide in ischemic stroke mice and a brain endothelial cell line","volume":"38","author":"Xu","year":"(2020)","journal-title":"Neurotox Res"},{"key":"R97-3-20230626","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3892\/ijmm.2013.1450","article-title":"Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease","volume":"32","author":"Zhao","year":"(2013)","journal-title":"Int J Mol Med"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.375299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:09:15Z","timestamp":1787760555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.375299"}},"subtitle":["clinical applications based on preclinical findings"],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/1673-5374.375299","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}